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Combination of ibrutinib and chemotherapy pro-
duced a durable remission in multiply relapsed dif-
fuse large B-cell lymphoma leg type with mutant
MYD88 and wildtype CD79
The mutant Myd88L265P protein promotes lym-
phoma cell survival in diffuse large B-cell lymphoma
(DLBCL) by activating NF-κB via Irak-4. On the other
hand, constitutively activated signaling of the B-cell
receptor (BCR), encoded by CD79A/B, activates NF-κB
via Bruton’s tyrosine kinase (Btk). Although the Btk
inhibitor ibrutinib has demonstrated remarkable clinical
activity in Waldenström’s macroglobulinemia (WM), an
indolent lymphoma characterized by a very high fre-
quency of the L265P MYD88 mutation, ibrutinib, as a
single agent, has demonstrated limited activity in
DLBCL, including no response in 7 DLBCL patients with
L265P MYD88 and wildtype CD79.1 Here, we report a
case in which ibrutinib, in combination with chemother-
apy, produced durable remission in multiply relapsed
cutaneous DLBCL leg type with L265P MYD88 and
wildtype CD79. Case Report:  A woman in her late 70s
presented with numbness and skin nodules on her left
foot in the spring of 2013. Subsequently, she developed
multiple enlarging skin lesions, severe pain in both legs,
and progressive weakness of the left foot. Skin biopsy
confirmed the diagnosis of cutaneous DLBCL leg type,
with the following immunophenotype: CD20+,
CD79a+, CD10-, BCL6+, BCL2+, and Mum1+, which
was consistent with the activated B-cell-like (ABC) sub-
type of DLBCL.  Positron emission tomography and
computed tomography (PET/CT) scan demonstrated
multiple Fludeoxyglucose (18F) (FDG) avid nodules in the
lower extremities and FDG avid thickening of the proxi-
mal left S1 nerve, but no lymphadenopathy. MRI of the
spine demonstrated enhancing intrathecal nodular densi-
ties, excessive epidural enhancement at the base of the
neural canal, and asymmetric thickening and enhance-
ment of the left S1 nerve root. The patient was treated
with 1 cycle of R-CHP (rituximab, cyclophosphamide,
doxorubicin, and prednisone, i.e., “R-CHOP” omitting
“O” vincristine due to preexisting left foot drop), with a
plan to add lenalidomide as soon as its off-label use was
approved by her insurance company.  However,
lenalidomide was denied; the plan was therefore revised
to R-EPCH (rituximab, etoposide, prednisone,
cyclophosphamide, and doxorubicin, i.e., “R-EPOCH”
omitting “O” vincristine). Because of the abnormal MRI
and PET/CT results in the spinal cord and S1 nerve root,
these sites were presumed to be lymphoma and treated
with high dose intravenous methotrexate, administered
after R-CHP/R-EPCH, and intrathecal
methotrexate/cytarabine, as part of the upfront treat-
ment.  Altogether, the patient received 1 cycle of R-CHP,
5 cycles of R-EPCH, 4 intrathecal injections of
methotrexate/cytarabine, and 4 cycles of high-dose
intravenous methotrexate.  She required no dose reduc-
tion of any drugs, except for the planned omission of
vincristine. Most of her symptoms had resolved by the
time she finished 3 cycles of chemotherapy, with the
exception of left foot drop which improved partially.
Following completion of 1x R-CHP and 3x R-EPCH, an
interim PET/CT scan demonstrated complete response
(CR).  Another PET/CT was done after all planned
chemotherapies were completed in January 2014, again
demonstrating CR. She then underwent radiation thera-
py of the S1 nerve root and completed the treatment by
the end of January 2014. However, she relapsed in May
2014 with multiple small skin lesions, which were biop-
sied and proven to be DLBCL leg type. The patient was
not a candidate for transplantation due to advanced age;
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Figure 1. PET/CT images pre- and post-treatment. Patient underwent a PET/CT scan before and after receiving ibrutinib+R-EPOCH x 4 cycles. Images matching
the comparable anatomic positions in the coronal and transverse planes were presented.     
she therefore enrolled in a phase I clinical trial evaluating
TGR-1202, a phosphatidylinositol-3-kinase delta
inhibitor. In the first cycle, she clinically had stable dis-
ease.  In the midst of cycle 2, she developed many skin
lesions consistent with her lymphoma.  PET/CT results
were consistent with progression of disease (POD). The
patient then received three cycles of R-ICE (rituximab,
ifosfamide, carboplatin, etoposide), which resolved all
the skin lesions and a severely inflamed right 3rd toe.
However, she developed new skin lesions before the
planned post-treatment week 6 PET/CT. Subsequently,
the patient enrolled in a phase I clinical trial evaluating
the combination of 5-azacitidine and romidepsin, and
had POD during cycle 1.  The patient then received two
cycles of an off-label therapy comprising liposomal dox-
orubicin 20 mg/m2 on day 1, rituximab 375 mg/m2 on
day 1, lenalidomide 5 mg daily on days 1-10, and dexam-
ethasone 40 mg on days 1, 8, and 15 on 21-day cycles,
and achieved clinically stable disease. However, she
developed severe fatigue, dizziness, and hearing loss, all
of which were thought most likely to be related to
lenalidomide.  Finally, she received one cycle of an off-
label treatment comprising liposomal doxorubicin 10
mg/m2 on days 1 and 8, rituximab 375 mg/m2 on day 1,
and subcutaneous bortezomib 1.3 mg/m2 on days 1 and
8 on a 21-day cycle. However, she had evidence of POD
before any further treatment.  By April 2015 she had
developed, for the first time, large nodal masses in the
mediastinum, abdomen, and pelvis, in addition to
numerous skin lesions with non-healing large ulcers in
the right leg. An ulcer on the right leg was biopsied and
confirmed to be DLBCL leg type. At that time, the
patient was deteriorating rapidly, and was not a candi-
date for clinical trials. Since emerging evidence suggest-
ed that ABC-DLBCL, compared to the germinal center
B-cell (GCB) subtype, may respond to ibrutinib,2 we rec-
ommended ibrutinib and R-EPOCH to this patient with
ABC-DLBCL. The patient was started on R-EPOCH
with ibrutinib in April 2015, and achieved a CR with 4
cycles of the regimen (Figure 1).  Due to neuropathy,
cytopenia, and fatigue, she received 50% dose reduction
of vincristine for C1-4, and required 10% dose reduc-
tion of cyclophosphamide for C2-4, reduction of ibruti-
nib from 560 to 420 mg daily for C2-4, and 20% dose
reduction of doxorubicin for C3-4. The patient then
started maintenance ibrutinib at 560 mg daily in June
2015. In March 2016 she developed severe fatigue,
weight loss, and was unable to stand up. Extensive
workup for relapse was negative, and she improved
after holding ibrutinib for 1 week.  She then resumed
ibrutinb at 420 mg daily, but had to discontinue it per-
manently in July 2016 due to severe diarrhea which did
not respond to further dose reduction. The patient
remains in remission with a negative PET/CT scan in
February 2017. To understand any potential mecha-
nisms of this remarkable response, we performed next
generation sequencing of 467 genes (http://
pathology.columbia.edu/diagnostic/PGM/pdf/cccp_gene_list.
pdf) using tumor DNA extracted from the tissues biop-
sied immediately prior to starting ibrutinib. The results
revealed L265P MYD88 and wildtype CD79A/B.
Additional mutations were detected in the following
genes: B2M, CREBBP, STAT6, CREBBP, GRIN2A, SS18,
DOT1L, MEF2B, BARD1, CUL3, EWSR1, KDR, FAT1,
FLT4, NOTCH4, CCND3, FAM123B, ATRX, and CIITA.
Discussion: The L265P mutant of Myd88 was originally
discovered in up to 29% of ABC-DLBCL, and was
demonstrated to promote cell survival by activating 
NF-κB via Irak-4.3 Later, MYD88 L265P was found in
more than 90% of WM.4 Although Myd88 L265P acti-
vates Btk in WM, there is no such a link (between
Myd88 L265P and Btk) in DLBCL.5 Clinically, ibrutinib
produces a major response in over 90% of WM, proba-
bly because the drug blocks Btk signaling, which is oth-
erwise activated by Myd88 L265P6. In contrast, the
response rate of DLBCL to ibrutinib is low, at 5 and 37%
for GCB- and ABC-DLBCL, respectively.1 Interestingly,
none of the 7 patients with MYD88 L265P and wildtype
CD79 responded. The patient in this report had multiply
relapsed ABC-DLBCL leg type with MYD88 L265P and
wildtype CD79, and achieved durable remission, now
exceeding 20 months, with the regimen of ibrutinib and
R-EPOCH. Given that R-EPCH in the upfront treatment
produced a short-lived remission for this patient, a plau-
sible explanation is that ibrutinib may have acted by
overcoming resistance to R-EPOCH in DLBCL cells.
Alternatively, ibrutinib as a single agent might similarly
produce a favorable response in this patient; a less likely
scenario which would suggest that the roles and rela-
tionship of Myd88 L265P and Btk may be substantially
different in DLBCL leg type versus nodal DLBCL, as
reported by Wilson et al.1 Ibrutinib has been reported, in
a small retrospective study, to produce an encouraging
response rate of 50% in primary CNS lymphoma of the
non-germinal center subtype,7 an extranodal DLBCL
known for activated BCR signaling and high mutation
rates of MYD88 and CD79.8 DLBCL leg type is associat-
ed with activated BCR, although the mutation frequen-
cies of MYD88 and CD79 are comparable to nodal
DLBCL.9 A favorable response to ibrutinib in these enti-
ties of DLBCL is likely achievable only when Btk plays a
key role in transmitting pathologically dominant BCR
signaling; and a poor response to ibrutinib may be
expected where BCR signaling is not important or is not
transmitted primarily by Btk.  However, the exact molec-
ular or genetic predictors for response to ibrutinib, as a
single agent or in combination with chemotherapies,
remain poorly understood. This challenge highlights the
need for more clinical trials.  For those patients with
relapsed ABC-DLBCL leg type who are not candidates
for clinical trials, our results suggest that the combina-
tion of ibrutinib and R-EPOCH has the potential to pro-
duce durable remission even when mutant MYD88 and
wildtype CD79 coexist, and when R-EPOCH has previ-
ously failed. In such cases, the dosage and duration of
ibrutinib and R-EPOCH need to be determined carefully
for individual patients as safety data are lacking.
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